Creatine News and Research

RSS

Creatine is an endogenous amino acid which is synthesized from simpler amino acids, namely glycine, arginine and the sulfur-containing amino acid methionine. Approximately 95 percent of creatine in the body is stored in skeletal muscle.

Study looks at factors that affect physical recovery after participation in ultramarathon

Ultramarathon runners can expect an approximate five-to-seven-day subjective recovery post race, according to research presented this week at the Association of Academic Physiatrists Annual Meeting in Sacramento, Calif. The study also looked at factors that affect physical recovery and a runner's ability to return to full running speed after participation in an ultramarathon.

19 Feb 2016

Compared to monotherapy combination of pills for advanced skin cancer extends survival

The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.3 months)

23 Nov 2015

Sickle cell disease treatment may help protect kidney function in patients

A drug used to treat sickle cell disease may provide an added benefit of protecting patients' kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

20 Nov 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk

A new study by researchers at the Universities of Montana, Valle de México, Boise State, and North Carolina, the Centro de Ciencias de la Atmósfera, Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, and Centro Médico Cozumel heightens concerns over the detrimental impact of air pollution on hippocampal metabolites as early markers of neurodegeneration in young urbanites carrying an allele 4 of the apolipoprotein E gene (APOE).

26 Sep 2015

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

28 Jul 2015

Necrotising autoimmune myopathy requires early, aggressive treatment

Researchers call for the prompt recognition of necrotising autoimmune myopathy and aggressive early treatment with a combination of intravenous immune globulin, corticosteroids and a steroid-sparing agent for 3 months.

27 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

Health food stores promote adult-only dietary supplements to minors

Fifteen year olds are not only able to buy over-the-counter dietary supplements from a sampling of health food stores across the country, the staff at those stores actually went so far as to recommend certain products, despite labels reading "for adult use only."

27 Apr 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Mar 2015

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1.

13 Feb 2015

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Doctor's Best has introduced three new sports nutrition powders – Creatine, Branched Chain Amino Acids (BCAA) and L-Arginine - into its science-based supplement portfolio.

13 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

Alzheimer's drug Aricept (donepezil) linked to serious side effects

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown (rhabdomyolysis) and a neurological disorder called neuroleptic malignant syndrome (NMS).

21 Jan 2015

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

Experimental agent TRO40303 ineffective in patients with heart attack

The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today as a Hot Line the ESC Congress 2014 with simultaneous publication in the European Heart Journal.

1 Sep 2014

Researchers use new gene editing method to correct mutation that leads to DMD

UT Southwestern Medical Center researchers successfully used a new gene editing method to correct the mutation that leads to Duchenne muscular dystrophy (DMD) in a mouse model of the condition.

17 Aug 2014

7.0T NMR spectroscopy detects lesions in hippocampal neurons of Alzheimer's disease

Magnetic resonance spectroscopy can quantitatively analyze in vivo abnormalities of biochemical metabolism within brain tissue in a noninvasive and non-radioactive manner.

6 Aug 2014

Creatine News and Research

Further Reading

Study looks at factors that affect physical recovery after participation in ultramarathon

Compared to monotherapy combination of pills for advanced skin cancer extends survival

Sickle cell disease treatment may help protect kidney function in patients

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

New study heightens concerns over detrimental impact of air pollution on gene associated with AD risk

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's disease

Necrotising autoimmune myopathy requires early, aggressive treatment

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Health food stores promote adult-only dietary supplements to minors

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Doctor's Best adds three new sports nutrition powders to its science-based supplement portfolio

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Alzheimer's drug Aricept (donepezil) linked to serious side effects

Combination treatment prevents disease progression in patients with advanced melanoma

Experimental agent TRO40303 ineffective in patients with heart attack

Researchers use new gene editing method to correct mutation that leads to DMD

7.0T NMR spectroscopy detects lesions in hippocampal neurons of Alzheimer's disease

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News